Other Operating Income - Narrative (Details) - USD ($) $ in Millions |
1 Months Ended | 12 Months Ended |
|---|---|---|
Oct. 31, 2023 |
Dec. 31, 2025 |
|
| Disclosure of attribution of expenses by nature to their function [line items] | ||
| Incentive refund period (in years) | 5 years | |
| AbbVie | ||
| Disclosure of attribution of expenses by nature to their function [line items] | ||
| Collaborative arrangements amount of preclinical milestones payment received | $ 30 | |
| Collaborative arrangement maximum additional development milestone payments to be received on exercise of option | 50 | |
| Collaborative arrangement maximum regulatory milestone payments to be received on exercise of option | 190 | |
| Collaborative arrangement maximum commercial milestone payments to be received on exercise of option | $ 325 |